Postdeposition dispersion of aerosol medications using surfactant carriers

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 21, Issue 4, 2008, Pages 361-369

  Marcinkowski, Amy L ^a   Garoff, Stephen ^b   Tilton, Robert D ^c   Pilewski, Joseph M ^d   Corcoran, Timothy E ^d  

^a University of Pittsburgh   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

^c CARNEGIE MELLON UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Airway model; Airway surface liquid; Cystic fibrosis; Surfactant

Indexed keywords

ANTIBIOTIC AGENT; CALFACTANT; CETRIMIDE; DODECYL SULFATE SODIUM; FLUORESCENT DYE; SODIUM CHLORIDE; SURFACTANT; TYLOXAPOL;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHUS MUCOSA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; EPITHELIUM CELL; HUMAN; HUMAN CELL; NONHUMAN; STOMACH MUCUS;

AEROSOLS; ANIMALS; BIOLOGICAL PRODUCTS; CELLS, CULTURED; CETRIMONIUM COMPOUNDS; CYSTIC FIBROSIS; DRUG CARRIERS; EPITHELIAL CELLS; GASTRIC MUCOSA; HUMANS; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; PULMONARY SURFACTANTS; SODIUM DODECYL SULFATE; SURFACE-ACTIVE AGENTS; SWINE; TISSUE DISTRIBUTION;

EID: 57149101389     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2008.0699     Document Type: Article

References (49)

1. Hirsh AJ: Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Adv Drug Deliv Rev. 2002;54:1445-1462.
2. Knowles MR, and Boucher RC: Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002;109:571[ndvo577.
3. Mall M, Grubb BR, Harkema JR, O'Neal WK, and Boucher RC: Increased airway epithelial Na- absorption produces cystic fibrosis-like lung disease in mice. Nat Med. 2004;10:487-493.
4. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, and Boucher RC: Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95:1005-1015.
5. Frizzell RA, and Pilewski JM: Finally, mice with CF lung disease. Nat Med. 2004;10:452-454.
6. Brown JS, Zeman KL, and Bennett WD: Regional deposition of coarse particles and ventilation distribution in healthy subjects and patients with cystic fibrosis. J Aerosol Med. 2001;14:443-454.
7. Svartengren K, Lindestad PA, Svartengren M, Bylin G, Philipson K, and Camner P: Deposition of inhaled particles in the mouth and throat of asthmatic subjects. Eur Respir J. 1994;7:1467-1473.
8. Corcoran TE: Inhaled delivery of aerosolized cyclosporine. Adv Drug Deliv Rev. 2007.
9. Smaldone GC, and Palmer LB: Aerosolized antibiotics: current and future. Respir Care. 2002;45:667-675.
10. Malmsten M: Surfactants and Polymers in Drug Delivery, Drugs and the Pharmaceutical Sciences. Marcel Dekker, Inc, New York, 2002.
11. Adamson AW: Physical Chemistry of Surfaces. John Wiley & Sons, Inc, New York, 1960.
12. Mate CM: Application of disjoining and capillary pressure to liquid lubricant films in magnetic recording. J Appl Phys. 1992;72:3084-3090.
13. Bachofen H, Schurch S, Urbinelli M, and Weibel ER: Relations among alveolar surface tension, surface area, volume, and recoil pressure. J Appl Physiol. 1987;62:1878-1887.
14. Im Hof V, Gehr P, Gerber V, Lee MM, and Schurch S: In vivo determination of surface tension in the horse trachea and in vitro model studies. Respir Physiol. 1997;109:81-93.
15. Kirkness JP, Eastwood PR, Szollosi I, Platt PR, Wheatley JR, Amis TC, and Hillman DR: Effect of surface tension of mucosal lining liquid on upper airway mechanics in anesthetized humans. J Appl Physiol. 2003;95:357-363.
16. Escolar JD, Escolar MA, Guzman J, and Roques M: Morphological hysteresis of the small airways. Histol Histopathol. 2003;18:19-26.
17. Grotberg JB, Halpern D, and Jensen OE: Interaction of exogenous and endogenous surfactant: spreading-rate effects. J Appl Physiol. 1995;78:750-756.
18. Kharasch VS, Sweeney TD, Fredberg J, Lehr J, Damokosh AI, Avery ME, and Brain JD: Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis. 1991;144:909-913.
19. van't Veen A, Mouton JW, Gommers D, and Lachmann B: Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. Br J Pharmacol. 1996;119:1145-1148.
20. Nimmo AJ, Carstairs JR, Patole SK, Whitehall J, Davidson K, and Vink R: Intratracheal administration of glucocorticoids using surfactant as a vehicle. Clin Exp Pharmacol Physiol. 2002;29:661-665.
21. Fajardo C, Levin D, Garcia M, Abrams D, and Adamson I: Surfactant versus saline as a vehicle for corticosteroid delivery to the lungs of ventilated rabbits. Pediatr Res. 1998;43(4 Pt 1):542-547.
22. Hughes WT, Sillos EM, LaFon S, Rogers M, Woolley JL, Davis C, Studenberg S, Pattishall E, Freeze T, Snyder G, and Staton S: Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia. J Infect Dis. 1998;177:1046-1056.
23. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, and Ramsey B: Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167:841-849.
24. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, and Smith AL: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340:23-30.
25. Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, and Lechtzin N: Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 2007;132:562-568.
26. Griese M, Bufler P, Teller J, and Reinhardt D: Nebulization of a bovine surfactant in cystic fibrosis: a pilot study. Eur Respir J. 1997;10:1989-1994.
27. Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, Pattishall EN, Barrett J, Engle M, Perret KA, and Rubin BK: Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA. 1997;278:1426-1431.
28. Rubin BK: Mucolytics, expectorants, and mucokinetic medications. Respir Care. 2007;52:859-865.
29. Girod de Bentzmann S, Pierrot D, Fuchey C, Zahm JM, Morancais JL, and Puchelle E: Distearoyl phosphatidylglycerol liposomes improve surface and transport properties of CF mucus. Eur Respir J. 1993;6:1156-1161.
30. Walther FJ, Hernandez-Juviel JM, Gordon LM, Waring AJ, Stenger P, and Zasadzinski JA: Comparison of three lipid formulations for synthetic surfactant with a surfactant protein B analog. Exp Lung Res. 2005;31:563-579.
31. Schott H: Comparing the surface chemical properties and the effect of salts on the cloud point of a conventional nonionic surfactant, octoxynol 9 (Triton X-100), and of its oligomer, tyloxapol (Triton WR-1339). J Colloid Interface Sci. 1998;205:496-502.
32. Zhang ZG, and Yin H: Interaction of nonionic surfactant AEO9 with ionic surfactants. J Zhejiang Univ Sci B. 2005;6:597-601.
33. Devor DC, Bridges RJ, and Pilewski JM: Pharmacological modulation of ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia. Am J Physiol Cell Physiol. 2000;279:C461-C479.
34. Tarran R, Grubb BR, Gatzy JT, Davis CW, and Boucher RC: The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol. 2001;118:223-236.
35. Samet JM, and Cheng PW: The role of airway mucus in pulmonary toxicology. Environ Health Perspect. 1994;102(Suppl 2):89-103.
36. Boucher RC: New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J. 2004;23:146-158.
37. Pilewski JM, and Frizzell RA: Role of CFTR in airway disease. Physiol Rev. 1999;79(Suppl):S215-S255.
38. Carlstedt IS, sheehan JK, Corfield AP, Gallagher JT: Mucous glycoproteins: a gel of a problem. Essays Biochem. 1985;20:40-76.
39. Allen A: Physiology of the Gastrointestinal Tract. Raven Press, New York, 1981.
40. Strous GJ, and Dekker J: Mucin-type glycoproteins. Crit Rev Biochem Mol Biol. 1992;27:57-92.
41. King M, Rubin BK: Pharmacological approaches to discovery and development of new mucolytic agents. Adv Drug Deliv Rev. 2002;54:1475-1490.
42. King M, and Rubin BK: Mucus-controlling agents: past and present. Respir Care Clin N Am. 1999;5:575-594.
43. Widdicombe JH: Regulation of the depth and composition of airway surface liquid. J Anat. 2002;201:313-318.
44. Boat TF, Cheng PW, and Wood RE: Tracheobronchial mucus secretion in vivo and in vitro by epithelial tissues from cystic fibrosis and control subjects. Mod Probl Paediatr. 1977;19:141-152.
45. Scawen M. and Allen A: The action of proteolytic enzymes on glycoproteins form pig gastric mucin. Biochem J. 1977;163:363-368.
46. Felgentreff K, Beisswenger C, Griese M, Gulder T, Bringmann G, and Bals R: The antimicrobial peptide cathelicidin interacts with airway mucus. Peptides. 2006;20:3100-3106.
47. Bhat PG, Flanagan DR, and Donovan MD: Drug diffusion through cystic fibrotic mucus: steady-state permeation, rheologic properties, and glycoprotein morphology. J Pharm Sci. 1996;85:624-630.
48. Griese M, Essl R, Schmidt R, Ballmann M, Paul K, Rietschel E, and Ratjen F: Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients. Respir Res 2005;6:133.
49. Postle AD, Mander A, Reid KB, Wang JY, Wright SM, Moustaki M, and Warner JO: Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis. Am J Respir Cell Mol Biol. 1999;20:90-98.